Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab and Ipilimumab for Chemo-radio-immunotherapy Followed by Maintenance Therapy With Nivolumab and Ipilimumab for Primary Treatment in Locally Advanced Cervical Cancer Patients

NCT05504642 is registered in ClinicalTrials.gov with Universitätsklinikum Köln as lead sponsor.

NCT NCT05504642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05504642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab and Ipilimumab for Chemo-radio-immunotherapy Followed by Maintenance Therapy With Nivolumab and Ipilimumab for Primary Treatment in Locally Advanced Cervical Cancer Patients
Lead sponsor
Universitätsklinikum Köln
Phase
Phase 2
Overall status
Withdrawn
Start date
November 1, 2023
Completion date
July 31, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer ≥ figo iib and or lymph node metastases